NEWS
-
2021/12/08 Correctseq
Dr. Xiaodun Mou Joins CorrectSequence Therapeutics as CEO
CorrectSequence Therapeutics (Correctseq), founded in 2020, has announced the appointment of Dr. Xiaodun (Susan) Mou as the Chief Executive Officer (CEO), in charge of general operation of the company. Correctseq is a cutting-edge biotechnology company leading the evolution of new gene editing technologies with a special focus on base editing for the permanent cure of genetic diseases to benefit global patients. Together with its accomplishments of series A financial raising, the opening of new research laboratories at Starthub Incubator in Shanghai Zhangjiang Innovation Center, the onboarding of Dr. Mou as CEO will drive the development of Correctseq to the new era. Dr. Mou will lead the clinical application of base editing technology, the expansion of therapeutic pipelines, the establishment of global standard CMC platform and the cGMP manufacturing of gene editing medicines.
-
2021/03/27 SDDA
Turning a Scissor into a Pen, CRISPR 2.0 Era is Coming
In face of tens of thousands of unsolved difficult diseases, gene editing technology known as "God's scalpel" is expected. Like turning knives into pens, several young Chinese scientists in Zhangjiang of Shanghai are committed to developing novel gene editors without making a double-stranded break in the DNA, directly modifying the wrong genetic information. In the trend of entrepreneurship, they want to develop the advanced gene editing technology into a precision genetic therapy of variety of genetic and tumor diseases as soon as possible.
-
2021/01/10 Correctseq
CorrectSequence Therapeutics (Correctseq), a pioneer gene editing biotechnology company, recently completed an angel round of financing of 40 million RMB (approximately USD 6 million). This round of financing is jointly led by Zoo Capital and New Alliance Capital, followed by Sequoia China and TF Capital, and signed a global exclusive permanent authorization agreement with ShanghaiTech University with a total amount of more than 170 million RMB (approximately USD 25 million).
-
2021/01/04 Correctseq
Co-founder of Correctseq, Professor Li Yang was invited to participate in the theme interview of the 6th BiG IMPACT annual conference on " Transforming from Papers to Product, the Difficulties and Path Breakthrough!".